← Eichor
Study identifier: NCT02421718 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Standard Follow-up Program (SFP) for Lung Cancer Patients Treated With Radiotherapy or Chemoradiation

Condition: Lung Cancer  ·  Sponsor: University Medical Center Groningen

PhaseN/A
Planned participants10000
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Motive: In order to improve the treatment technique, a comprehensive follow-up program is needed to obtain all relevant patient, treatment and toxicity data from lung cancer patients. Goal: To set-up and maintain a database containing treatment results in terms of tumor control, side effects, complications and patient-reported quality of life. A standard database of patients receiving photon treatment will be created. These data are then linked to dose-volume data of radiotherapy, with the aim to build prediction models for both tumor control and toxicity after radio (chemo) therapy that can later be used for selecting patients for proton treatment.

This description comes directly from the study's public registry record.

Talk to the study team

Robin Wijsman, MD PhD  ·  +31503615532  ·  r.wijsman@umcg.nl

Always discuss trial participation with your own doctor first.

Locations (1)

University Medical Center GroningenGroningen, Provincie Groningen, NetherlandsRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT02421718